These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 4038577)

  • 21. Cefmenoxime: clinical evaluation.
    Baker RL; Perkins RL
    Am J Med; 1984 Dec; 77(6A):53-9. PubMed ID: 6097126
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aztreonam in the treatment of aerobic, gram-negative bacillary infections in pediatric patients.
    Trujillo H; Harry N; Arango A; Benítez G; Restrepo F; Mejía GI; Castrillón AL
    Chemotherapy; 1989; 35 Suppl 1():25-30. PubMed ID: 2731447
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aztreonam therapy for serious gram-negative infections in children.
    Stutman HR; Chartrand SA; Tolentino T; Friedhoff L; Marks MI
    Am J Dis Child; 1986 Nov; 140(11):1147-51. PubMed ID: 3766490
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of aztreonam in the treatment of patients with renal failure.
    Sion ML; Pyrpasopoulos M; Nicolaidis P; Papagianni C; Tsurutsoglu G
    Rev Infect Dis; 1991; 13 Suppl 7():S652-4. PubMed ID: 2068477
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of aztreonam in the treatment of severe bacterial infections.
    Romero-Vivas J; Rodríguez-Créixems M; Bouza E; Hellín T; Guerrero A; Martínez-Beltrán J; García de la Torre M
    Antimicrob Agents Chemother; 1985 Aug; 28(2):222-6. PubMed ID: 3834832
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment with aztreonam or tobramycin in critical care patients with nosocomial gram-negative pneumonia.
    Schentag JJ; Vari AJ; Winslade NE; Swanson DJ; Smith IL; Simons GW; Vigano A
    Am J Med; 1985 Feb; 78(2A):34-41. PubMed ID: 3881947
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overall clinical experience with aztreonam in the treatment of intraabdominal infections.
    Henry SA
    Rev Infect Dis; 1985; 7 Suppl 4():S729-33. PubMed ID: 3909331
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro activity of aztreonam against gram negative bacteria from clinical specimens and its comparison with other commonly used antibiotics.
    Qadri SM; Belobraydic KA
    Methods Find Exp Clin Pharmacol; 1986 Apr; 8(4):223-6. PubMed ID: 3088346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aztreonam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Brogden RN; Heel RC
    Drugs; 1986 Feb; 31(2):96-130. PubMed ID: 3512234
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of aztreonam versus tobramycin for aerobic gram-negative bacilli lower respiratory tract infections.
    Rodriguez JR; Ramirez-Ronda CH
    Am J Med; 1985 Feb; 78(2A):42-3. PubMed ID: 4038578
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aztreonam in the treatment of serious gram-negative infections in the elderly.
    Deger F; Douchamps J; Freschi E; Thys JP; Nève P; Herchuelz A
    Int J Clin Pharmacol Ther Toxicol; 1988 Jan; 26(1):22-6. PubMed ID: 3403089
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical experience with aztreonam in four Mediterranean countries.
    Daikos GK
    Rev Infect Dis; 1985; 7 Suppl 4():S831-5. PubMed ID: 2934787
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical evaluation of aztreonam (AZT) in the treatment of complicated urinary tract infections].
    Mizutani S; Iwao N; Miyoshi S; Kameoka H; Yano H; Kishimoto T; Sakurai T; Wakatsuki A; Nakamura T; Honda M
    Hinyokika Kiyo; 1989 Dec; 35(12):2155-61. PubMed ID: 2694836
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral ciprofloxacin in the treatment of elderly patients with complicated urinary tract infections due to trimethoprim/sulfamethoxazole-resistant bacteria.
    Preheim LC; Cuevas TA; Roccaforte JS; Mellencamp MA; Bittner MJ
    Am J Med; 1987 Apr; 82(4A):295-300. PubMed ID: 3555051
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical efficacy of carumonam.
    Drabu YJ; Mehtar S; Blakemore PH
    Drugs Exp Clin Res; 1988; 14(10):665-7. PubMed ID: 3246211
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bacterial incidence and antibiotic sensitivity pattern in moderate and severe infections in hospitalised patients.
    Ghosh A; Karmakar PS; Pal J; Chakraborty N; Debnath NB; Mukherjee JD
    J Indian Med Assoc; 2009 Jan; 107(1):21-2, 24-5. PubMed ID: 19588683
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Infections due to gram-negative bacteria: an overview.
    Neu HC
    Rev Infect Dis; 1985; 7 Suppl 4():S778-82. PubMed ID: 3909337
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of low dose aztreonam in the treatment of moderate to severe gram-negative bacterial infections.
    Clergeot A; Steru D; Rosset MA; Carbon C
    J Antimicrob Chemother; 1989 May; 23(5):753-8. PubMed ID: 2759924
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative study of aztreonam and cefamandole in the treatment of serious urinary tract infections.
    Tsouroutsoglou W; Sion ML; Stathopoulos GA; Kapoulas S; El-Messidi M; Paradelis AG
    Methods Find Exp Clin Pharmacol; 1983; 5(6):385-90. PubMed ID: 6684719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical studies of aztreonam in Japan.
    Hara K; Kobayashi H; Nishiura T; Yura J; Saito A
    Rev Infect Dis; 1985; 7 Suppl 4():S810-24. PubMed ID: 3909341
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.